IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The opening of our 1000th pharmacy in Karnataka marks an important step
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Full approval will depend on verification of clinical benefit in a confirmatory trial
Subscribe To Our Newsletter & Stay Updated